Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009650 | 1.00 | PARP1 (0.55) | PARP1PARP3TRPV1GAACNR1 | |
| SCHEMBL12009652 | 1.00 | PARP1 (0.55) | PARP1PARP3TRPV1GAACNR1 | |
| SCHEMBL12009653 | 1.00 | PARP1 (0.55) | PARP1PARP3TRPV1GAACNR1 | |
| SCHEMBL2956584 | 1.00 | PARP1 (0.55) | PARP1PARP3TRPV1GAACNR1 | |
| SCHEMBL10002224 | 0.94 | CNR1 (0.57) | PARP1PARP3TRPV1GAACNR1 | |
| SCHEMBL2957806 | 0.93 | PARP1 (0.60) | PARP1PARP3CYP3A4MAPK1HDAC1 | |
| SCHEMBL12714254 | 0.88 | CYP3A4 (0.55) | PARP1PARP3GAACYP3A4MAPK1 | |
| SCHEMBL12009638 | 0.88 | HPGD (0.61) | TRPV1GAAGRIA1OPRM1HDAC1 | |
| SCHEMBL12009633 | 0.88 | HPGD (0.61) | TRPV1GAAGRIA1OPRM1HDAC1 | |
| SCHEMBL12714246 | 0.86 | FFAR1 (0.63) | HDAC8ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546088-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES, IMMUNO-ALLERGICAL DISEASES AND ORGAN OR TISSUE TRANSPLANTATION REJECTION | NOVAREMED LTD (IL) | 2014-12-17 | — | — | EP | claimed |
| EP-2475361-B1 | N-SUBSTITUTED BENZENEPROPANAMIDES FOR USE IN THE TREATMENT OF PAIN AND INFLAMMATION | NOVAREMED LTD (IL) | 2019-11-06 | — | — | EP | disclosed |
| EP-1750691-B1 | COMPOUNDS FOR TREATMENT OF AIDS AND OTHER DISEASES | NOVAREMED LTD (IL) | 2016-08-10 | — | — | EP | disclosed |
| EP-1750691-B1 | COMPOUNDS FOR TREATMENT OF AIDS AND OTHER DISEASES | NOVAREMED LTD (IL) | 2016-08-10 | — | — | EP | disclosed |
| US-9199917-B2 | N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation | NOVAREMED LIMITED (IL) | 2015-12-01 | — | — | US | disclosed |
| US-9199917-B2 | N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation | NOVAREMED LIMITED (IL) | 2015-12-01 | — | — | US | disclosed |
| EP-2026775-B1 | USE OF SYK TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | NOVAREMED LTD (IL) | 2015-04-29 | — | — | EP | disclosed |
| US-20150080473-A1 | N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for use in the Treatment of Pain and Inflammation | NOVAREMED LIMITED (IL) | 2015-03-19 | — | — | US | disclosed |
| US-20150080473-A1 | N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for use in the Treatment of Pain and Inflammation | NOVAREMED LIMITED (IL) | 2015-03-19 | — | — | US | disclosed |
| EP-1546088-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES, IMMUNO-ALLERGICAL DISEASES AND ORGAN OR TISSUE TRANSPLANTATION REJECTION | NOVAREMED LTD (IL) | 2014-12-17 | — | — | EP | disclosed |
| US-7674829-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-03-09 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-20090306214-A1 | Use of Syk Tyrosine Kinase Inhibitors for the Treatment of Cell Proliferative Disorders | NOVAREMED LIMITED (IL) | 2009-12-10 | — | — | US | disclosed |
| US-20090306214-A1 | Use of Syk Tyrosine Kinase Inhibitors for the Treatment of Cell Proliferative Disorders | NOVAREMED LIMITED (IL) | 2009-12-10 | — | — | US | disclosed |
| WO-2007129226-A2 | USE OF SYK TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | NEW ERA BIOTECH LTD (VG) | 2007-11-15 | — | — | WO | disclosed |
| EP-1750691-A2 | COMPOUNDS FOR TREATMENT OF AIDS AND OTHER DISEASES | New Era Biotech Limited (VG) | 2007-02-14 | — | — | EP | disclosed |
| US-20060148874-A1 | Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions | NOVAREMED LIMITED (IL) | 2006-07-06 | — | — | US | disclosed |
| US-20050239898-A1 | Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions | NOVAREMED LIMITED (IL) | 2005-10-27 | — | — | US | disclosed |
| WO-2005092305-A2 | COMPOUNDS FOR TREATING AIDS AND OTHER DISEASES | NEW ERA BIOTECH LTD (VG) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148874-A1 | Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions | CCR4, CD4, CCR5 | PARP1 3809/4885PARP3 2843/4885TRPV1 2372/4885 |
| US-20150080473-A1 | N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for use in the Treatment of Pain and Inflammation | CNR2, CNR1, BTN3A1 | PARP1 1376/4885PARP3 918/4885TRPV1 73/4885 |
| US-20050239898-A1 | Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions | CCR4, CD4, CCR5 | PARP1 3809/4885PARP3 2843/4885TRPV1 2372/4885 |
| US-20090306214-A1 | Use of Syk Tyrosine Kinase Inhibitors for the Treatment of Cell Proliferative Disorders | SYK, BTK, LCK | PARP1 813/4885PARP3 1132/4885TRPV1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.